HeartWare International Inc. (NSDQ:HTWR) leavened some good news with a minor spot of bad news: Positive clinical and commercial data for its ventricular assist device balanced against a repair program and partial recall of some of the device’s controllers.
The Framingham, Mass.-based medical device maker said data from an international clinical trial and from commercial use of its HVAD device showed a survival rate of 90 percent after six months and an actuarial survival rate of 86 percent after a year. The data came from a 50-patient international study and from the first 50 commercial patients, according to a press release.